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A new paradigm of mucosal vaccination against human immunodeficiency virus (HIV) infec-
tion has been investigated in the macaque model. A vaccine consisting of inactivated simian
immunodeficiency virus (SIV)mac239 particles together with a living bacterial adjuvant
(either the Calmette and Guerin bacillus, Lactobacillus plantarum or Lactobacillus rhamno-
sus) was administered to macaques via the vaginal or oral/intragastric route. In contrast to
all established human and veterinary vaccines, these three vaccine regimens did not elicit
SIV-specific antibodies nor cytotoxicT-lymphocytes but induced a previously unrecognized
population of non-cytolytic MHCIb/E-restricted CD8+ T-regulatory cells that suppressed
the activation of SIV-positive CD4+ T-lymphocytes. SIV reverse transcription was thereby
blocked in inactivated CD4+ T-cells; the initial burst of virus replication was prevented and
the vaccinated macaques were protected from a challenge infection. For 3–14 months after
intragastric immunization, 24 macaques were challenged intrarectally with a high dose of
SIVmac239 or with the heterologous strain SIV B670 (both strains grown on macaques
PBMC). Twenty-three of these animals were found to be protected for up to 48 months
while all 24 control macaques became infected.This protective effect against SIV challenge
together with the concomitant identification of a robust ex vivo correlate of protection sug-
gests a new approach for developing an HIV vaccine in humans. The induction of this new
class of CD8+T-regulatory cells could also possibly be used therapeutically for suppressing
HIV replication in infected patients and this novel tolerogenic vaccine paradigm may have
potential applications for treating a wide range of immune disorders and is likely to may
have profound implications across immunology generally.
Keywords: inactivated SIV, bacterial adjuvants, BCG, lactobacilli, SIV replication, SIV vaccine, HIV vaccine, HIV
tolerogenic vaccine
INTRODUCTION
Since the first vaccination against the small pox virus by Edward
Jenner in 1796, all efficient vaccines against a viral infection have
been shown to elicit virus-specific neutralizing antibodies and
sometimes also cytotoxic T-lymphocytes (CTL) that prevent virus
infection or eradicate the virus rapidly after it enters the body (1).
So far, however, this process seems not to work for the human
immunodeficiency virus (HIV) type 1 infection since, despite
the tremendous advances in immunology and molecular biology
accomplished since HIV discovery in 1983 (2), results of vaccine
trials against HIV have indeed remained extremely poor (3). Only
one trial out of more than one hundred showed a modest and
short-lasting protection (4) while all the others did not induce any
protective immunity (antibodies or CTL) against the virus includ-
ing sadly the latest three randomized vaccine trials where more
volunteers were infected in the vaccine arm than in the placebo arm
(5–7); combining data from the three studies, there was an overall
hazard ratio of 1.33 (P < 0.01) associated with vaccination (8).
For the last 30 years,our group tried to suppress HIV replication
and fight HIV infection by pursuing several alternative immuno-
logical approaches. As early as 1986, we speculated that T4-cell
activation (whether triggered by the virus, viral proteins, or by any
other stimulus) was an absolute requirement for significant viral
replication (9). This suspicion, which is now commonly accepted
by scientists who study the pathogenesis of simian immunode-
ficiency virus (SIV) in macaques and of HIV in humans (8, 10,
11) suggested to us that it might be possible to inhibit virus repli-
cation by suppressing CD4+ T-cell activation (9). We tested the
possibility that viral replication might be controlled by adminis-
tering the immunosuppressive drugs cyclosporine or prednisolone
to infected patients. Both drugs were found to stabilize or increase
CD4+ T-cell counts in HIV-infected patients (12–15), probably by
preventing activation-induced apoptosis of non-infected CD4+
T-cells (16), but they did not control HIV-1 replication.
Since it was not possible to control viral replication by systemic
non-specific immune suppression, we then explored the capacity
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of dendritic cells loaded with ex vivo-inactivated virus to stimulate
HIV-specific cellular immunity (17, 18). Using this approach, we
were able to demonstrate that a therapeutic vaccine based on inac-
tivated HIV-loaded dendritic cells had a favorable impact on HIV
replication (19), a finding that was recently confirmed in HIV-
infected patients who had interrupted their antiviral therapy (20).
However, we did not pursue this project because the preparation of
dendritic cell-based vaccine was cumbersome and expensive and
was incompatible with a large scale use.
Instead of activating dendritic cells by loading them ex vivo with
inactivated HIV, we then investigated possibility of developing a
prophylactic anti-SIV vaccine by directly stimulating mucosal den-
dritic cells in vivo. We describe here the attempts we made during
the last 10 years to develop prophylactic mucosal vaccines using
inactivated SIV mac239 (iSIV) adjuvanted by non-pathogenic liv-
ing bacteria potentially able to cooperate with mucosal dendritic
cells. These experiments were performed in macaques of Chinese
origin, which best mimics HIV infection in humans (21, 22).
MATERIALS AND METHODS
ANIMALS
Colony-bred rhesus macaques (Macaca mulatta) of Chinese origin
were housed in accordance with the regulations of the National
Institutes of Health “Guide for the Care and Use of Laboratory
Animals.” The committee for animal studies of the Tropical Med-
icine Institute, Guangzhou, University of Chinese Medicine, has
approved the study and confirmed that it has been done appro-
priately. All animals were in good health, 2–4 years old, weighed
4–6 kg, and were seronegative for SIV, simian retrovirus, simian
T-cells lymphotropic virus 1, hepatitis B virus, and Herpes virus
simiae.
VACCINE PREPARATION
The vaccines used throughout this study were a mixture of
two components: the iSIV and a bacterial adjuvant, which was
either the Bacillus of Calmette & Guerin (BCG), the Lactobacillus
plantarum (LP), or the Lactobacillus rhamnosus (LR).
Bacterial preparations
Three bacterial preparations were used: the BCG, the LP, and the
LR. The BCG (strain SSI 1331, Sanofi-Pasteur) was used at a final
dose of 5× 106 or 7.5× 107 cfu for each (intravaginal or intra-
gastrical) vaccination or boost. Each dose of vaccine was freshly
prepared in 1 mL of RPMI. The LP (ATCC8014) was cultivated at
37°C in MRS medium with a rotation rate of 200 rpm until reach-
ing a final LP concentration of around 1010 cfu/ml (i.e., an optical
density of 1.0 at 600 nm). The LR (lcr35, Probionov, 15000 Auril-
lac, France) was received in lyophilized form at a concentration of
around 1× 1011 cfu/g.
Inactivated virus preparation
The virus production was performed in CEM174 cells inoculated
with SIVmac239 [see Lu et al. (23)]. Culture supernatants were
collected at peak viral production. In order to check what could
be the simplest and safest inactivation system, we tested three dif-
ferent modalities: when associated with the BCG, the virus was
inactivated with 250µM aldrithiol-2 (AT-2) in the same manner
as we did previously (18); when associated with LP, the virus was
inactivated with AT-2 and then by heat (56°C for 30 min) [see Lu
et al. (23)]; finally, when associated with LR, the virus was inacti-
vated in the simplest as possible manner, by heat (56°C for 30 min)
twice at 30 min-interval. The iSIV was inoculated to CEM174 cells
to verify the 100% inhibition of viral infectivity.
DELIVERY OF THE VACCINES
Monkeys were anesthetized with tiletamine hydrochloride
and intramuscular zolazepam (0.7 mg/kg) (after having fasted
overnight for those which were immunized via the intragastric
route).
Intravaginal immunization with iSIV+BCG
Monkeys were administered intravaginally 5 ml of a vaccine com-
prising 109 particles of iSIV and 5× 106 cfu of BCG (strain SSI
1331). A booster intravaginal immunization with the same dose
was applied 2 months later. Control animals remained naïve until
challenge.
Intragastric immunization with iSIV+BCG
Monkeys after having fasted overnight were anesthetized. They
were administrated intragastrically with 25 ml of PBS buffer and
half an hour later with 5 ml of a viral–bacterial preparation con-
taining 109 copies/ml of iSIV and 1.5× 107 cfu/ml of BCG in
maltodextrin (20%) solution. A booster intravaginal immuniza-
tion with the same dose was applied 2 months later. Control
animals received the same doses of BCG alone according to the
same protocol.
Intragastric immunization with iSIV+ LP or LR
The macaques were administrated intragastrically 30 ml of a
first preparation containing 4× 107 copies/ml of iSIV and
3× 109 cfu/ml of LP or LR in maltodextrin (20%) solution. Mon-
keys then received intragastrically 25 ml of the same prepara-
tion each 30 min for 3 h; the same protocol was performed over
five consecutive days. Overall, each macaque received a total of
3.5× 1010 copies of iSIV and 2.6× 1012 cfu of LP or LR. Control
animals received the same doses of LP alone, LR alone, or iSIV
according to the same protocol.
Overall, 37 macaques were vaccinated by one of the above-
mentioned protocols and 45 animals served as control.
SIV SUPPRESSION ASSAY: EX VIVO ANTIVIRAL ACTIVITY OF
VACCINE-INDUCED CD8+ T-CELLS
Autologous CD4+ T-cells from each animal purified by mag-
netic positive-labeling (MicroBeads, Miltenyi Biotec) were acutely
infected with SIVmac239 (10−3 multiplicity of infection) in the
presence or the absence of magnetically purified CD8+ T-cells
at a CD4/CD8 ratio of 1:3 and then stimulated with staphylo-
coccal enterotoxin B (SEB) and anti-CD3/anti-CD28 antibodies
for 16 h. After washing, the cells were cultivated in quadrupli-
cates in 96-well plates. Cultures were maintained in a final volume
of 200µl per well of RPMI 1640 medium containing 100 IU of
human rIL2 (Roche Diagnostics GmbH, Mannheim, Germany)
for 5 days. Viral loads were measured by a real-time RT-PCR in
culture supernatants collected at day 5 [see Lu et al. (23)]. Ex vivo
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antiviral activity was the ratio of geometric means of viral concen-
tration in the culture supernatants from the infected CD4+ target
cells only over the geometric means of viral concentration in the
supernatants from the mixed CD8+ and CD4+ T-cells.
VIRAL CHALLENGES
For 3–14 months after the administration of the vaccine or the
controls, vaccinated and control animals were inoculated intra-
venously with 50 MID100 (200 TCID50) or intrarectally with 2,500
MID100 (100,000 TCID50) of pathogenic SIVmac239 (cultivated
on macaques PBMC). Monkeys were rechallenged by intravenous
or intrarectal route with the same high doses of infectious SIV-
mac239. Eight macaques were intrarectally rechallenged with
100,000 TCID50 of pathogenic SIVB670 (a distinct strain of SIV
provided by F. Villinger, Emory University School of Medicine,
Atlanta, Georgia). SIVB670 was propagated in vitro using macaque
PBMC and the first passages of the original viral stocks were used
for challenge.
OTHER METHODS
For details on other methods used in this study (MHC class I
typing, assay for antibody responses to SIV, flow cytometry, SIV-
specific cell proliferation assay, SIV-specific ELISPOT assay, T-cell
suppression assay, T-cell cytotoxicity assay, viral loads measure-
ments, depletion of CD8+ T-cells in vivo, and statistical analysis),
see Section “Experimental Procedures” in Lu et al. (23).
RESULTS
MUCOSAL VACCINATION WITH INACTIVATED SIV AND BCG
We first tested a vaccine including iSIV as immunogen and the
BCG as a bacterial adjuvant (24). We chose the BCG because it
had been shown to interact with dendritic cells (25, 26) as well as
to stimulate cellular immunity in some types of cancers (27, 28).
Moreover, BCG had been given orally to several millions of people
in Brazil until 1974 without serious side effects (29).
Intravaginal immunization followed by intravenous challenge
Six macaques were administered intravaginally 5 ml of a vaccine
comprising 109 particles of iSIV and 5× 106 cfu of BCG (strain SSI
1331). A booster intravaginal immunization was applied 2 months
later. Two months later (i.e., 4 months after the initial vaccination),
the six animals were challenged by intravenous route with 200
TCID50 of SIVmac239. Simultaneously five vaccine-free control
animals were also challenged with the same dose of SIVmac239. Al
control macaques showed a typical primary infection with plasma
viral loads peaking at 106–107 viral copies/ml between days 10 and
14 post-challenge and then remaining high (>105 copies/ml) over
the next 60 days. They also developed high levels of PBMC SIV
DNA and became seropositive with high titers of SIV antibod-
ies. Among the six animals that received the intravaginal vaccine,
plasma viral RNA loads of two of them, after the usual peak (>106
copies/ml), decreased to lower set-point (<103 copies/ml) than
normal whereas their SIV DNA remained ≤1,000 copies/106 in
PBMC or lymph node cells. More surprisingly, the four remaining
macaques showed very low viral RNA and DNA peaks (≤103 SIV
RNA copies/ml and <103 SIV DNA copies//106 PBMC) by days
10–14, which dropped down to undetectable/hardly detectable
levels thereafter (Figures 1A,B).
Intravaginal immunization followed by intrarectal challenge
Seven new macaques were then administered intravaginally the
same vaccine with the same boosts while five controls ani-
mals remained vaccine-free. Four months later, the 12 animals
were challenged via the intrarectal route with 100,000 TCID50
of SIVmac239. The five control animals showed the same typ-
ical primary infection as described above. Moreover, three out
of the seven vaccinated animals showed also a primary infec-
tion resembling the usual one but with viral RNA and DNA
load set-points significantly lower than those observed in con-
trol animals. The new information was that four out of the seven
vaccinated macaques remained with undetectable levels of plasma
SIV RNA (<10 SIV RNA copies/ml) and PBMC proviral DNA
(<1 SIV DNA copies/106 PBMC) over the 60 days post-challenge
(Figures 1C,D).
Protection against repeated intravenous or intrarectal challenges
after intravaginal immunization
Among the four animals with undetectable viral loads follow-
ing intravenous challenge, three were tested for their long-term
capacity to fight new SIV challenges. For 2 and 8 months after
their initial intravenous challenge (i.e., 6 and 12 months after their
immunization), these three monkeys received a second and a third
intravenous challenge with the same dose of SIV239 (200 TCID50).
After each of these viral challenges, similar low plasma RNA SIV
peaks were observed at day 10 but by day 30, viral loads of all
three macaques had dropped down to undetectable levels. For 21
and 27 months after initial vaccination, the three macaques were
further challenged with SIVmac239, this time via the intrarec-
tal route (100,000 TCID50) and the three animals showed again
no detectable plasma virus (<10 SIV RNA copies/ml) while their
PBMC SIV DNA levels remained at the limit of positivity. Overall,
viral replication of these three vaccinated macaques remained sta-
bly suppressed as long as we tested it (28 months) in spite of five
SIV239 challenges (Figure 1E).
Oral (intragastric) immunization followed by intrarectal challenges
Four new macaques were then administered through a gastric tube
5 ml of a vaccine comprising iSIV and BCG. Vaccine administra-
tion was preceded and followed by the injection of 15 ml of 0.1 M
sodium bicarbonate in the macaques gastric tube. Booster vac-
cinations with the same preparations were repeated at days 30
and 60. Four control animals received BCG alone according to
the same protocol. An intrarectal viral challenge (100,000 TCID50
of SIVmac239) was then given to the eight animals at day 90.
The four control animals showed a typical primary infection with
a plasma viral peak between days 10 and 14 post-challenge. In
strong contrast, the four animals that received the vaccine were
sterilely protected as shown by their plasma SIV RNA and PBMC
SIV DNA loads, which remained undetectable from day 1 to 60
(Figures 1F,G).
In light of these unexpected mucosal vaccination successes,
we tested the SIV-specific antibody and cellular responses of
vaccinated macaques. Surprisingly again, SIV-specific antibodies
responses in intravaginally or intragastrically vaccinated macaques
were undetectable or extremely weak while all control mon-
keys raised anti-SIV antibodies and became seropositive. SIV
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FIGURE 1 | Plasma viral loads and PBMC and lymph nodes proviral
loads of rhesus macaques immunized with inactivated SIV and
BCG. (A,B) Plasma viral loads (A) and PBMC proviral loads (B) following
a challenge performed intravenously with SIVmac239 (200 TCID50) in six
macaques intravaginally immunized with iSIV and BCG and five control
monkeys; (C,D) plasma viral loads (C) and PBMC proviral loads
(D) following a challenge performed intrarectally with SIVmac239
(100,000 TCID50) in seven macaques intravaginally immunized with
inactivated SIV and BCG; (E) Plasma viral loads of three macaques
intravaginally immunized with inactivated SIV and BCG following three
intravenous and two intrarectal SIVmac239 challenges; (F,G) Plasma viral
loads (F) and PBMC and lymph nodes proviral loads (G) following a
challenge performed intrarectally with SIVmac239 (100,000 TCID50) in
four macaques intragastrically immunized with inactivated SIV and BCG
and four control monkeys immunized with inactivated BCG alone (ctrs:
control, vacs: vaccinated, LN: lymph nodes).
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Gag p27-specific interferon γ-releasing T-cell responses were
also undetectable by ELISPOT in vaccinated macaques (data not
shown).
Ex vivo antiviral activity of CD8+ T-lymphocytes in vaccinated
macaques
This surprising immunovirological picture, characterized by a
sterile immunity after intrarectal challenge, or complete virus
replication control after intravenous challenge in the majority
of mucosally vaccinated animals, in the absence of SIV-specific
humoral and cellular immune responses, prompted us to examine
whether SIV-specific non-conventional cellular responses could
exist. For that purpose, CD4+ and CD8+ T-cells were purified
from fresh PBMC of vaccinated or control animals. CD4+ T-cells
were then acutely infected with SIVmac239 and CD4+ T-cells and
CD4+ plus CD8+ T-cells were stimulated overnight with SEB plus
anti-CD3 and anti-CD28 antibodies and cultivated for 5 days. The
antiviral activity of the CD8+ T-cells was expressed as the ratio of
SIV RNA concentration in the supernatants of SIV-infected CD4+
T-cell cultures in the absence of CD8+ T-cells over the SIV RNA
concentration in corresponding cultures in the presence of CD8+
T-cells [for details, see “Method” in Ref. (23)]. Results of these
assays showed that CD8+ T-cells from the four out of seven intrav-
aginally vaccinated animals that were shown later to be protected
against intrarectal challenge, showed a strong antiviral activity
(ratio over 100), whereas CD8+ T-cells from the three animals,
which were later shown not to be protected against SIV infection
as well as CD8+ T-cells from those which were not vaccinated had
baseline levels of antiviral activity (ratio <50) (Figure 2A). Simi-
larly, in the four orally vaccinated macaques, which were all found
to be protected from an intrarectal challenge some weeks later,
the antiviral activity was over 100 (Figure 2B). Altogether, in this
group of vaccinated macaques, we observed a complete correla-
tion between the pre-challenge ex vivo antiviral activity of CD8+
T-cells and the protection observed after SIV challenge suggest-
ing that the CD8+ T-lymphocytes antiviral activity of vaccinated
macaques is an excellent predictive marker of protection against
SIV challenge.
Suppression of activation of SIV-specific CD4+ T-cells by
vaccine-induced CD8+ T-cells in vaccinated macaques
Since, the initiation of replication of SIV in macaques (or HIV in
humans) in vivo, as well as SIV (or HIV)-specific antibody and
CTL induction needs SIV (or HIV)-specific CD4+ T-cell activa-
tion (11),we suspected that the suppression of both SIV replication
and SIV-specific immune responses observed after mucosal vac-
cination with iSIV plus BCG could be the consequence of the
suppression of SIV-specific CD4+ T-cell activation [for details on
the method of CD4+ T-cell activation suppression, see “Method”
in Ref. (23)]. It was therefore reassuring to observe that SIV-
positive CD4+ T-cell activation was suppressed in the PBMC of
vaccinated macaques while remaining at the high level observed
in control samples when CD8+ T-cells were omitted from the test
sample (Figure 2C).
Altogether, the intravaginal co-administration of BCG and
inactivated SIV protected four out of six monkeys from an intra-
venous SIVmac239 challenge and four out of seven monkeys from
FIGURE 2 | Ex vivo antiviral activity and suppression of SIV positive
CD4+T-cell activation generated by vaccine-induced CD8+ T-cells of
rhesus macaques immunized with inactivated SIV and BCG. (A,B)
Ex vivo antiviral activity generated by vaccine-induced CD8+ T-cells in seven
(Continued)
www.frontiersin.org June 2014 | Volume 5 | Article 297 | 5
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Andrieu et al. Macaque oral vaccine against SIV
FIGURE 2 | Continued
rhesus macaques intravaginally immunized with inactivated SIV and BCG
and five control macaques (A) and in four rhesus macaques intragastrically
immunized with inactivated SIV and BCG and four control macaques
(B); (C) percentage (mean±SD) of the activation marker Ki-67 within SIV
Gag p27+ cells on the gated CD4+ T-cells in AT-2 SIV-pulsed PBMC
(depleted or not of CD8+ T-cells) taken from animals orally immunized with
inactivated SIV plus BCG or those immunized with BCG alone.
an intrarectal challenge while the intragastric administration of
the same vaccine preparation protected four out of four macaques
from an intrarectal challenge. Long-term protection (28 months)
associated with this new type of vaccine was maintained after
repeated intravenous and intrarectal challenges in the three ani-
mals where it was tested. In contrast, infection was observed in all
control animals. In the four out of six macaques protected from
an intravenous challenge, viral replication was completely con-
trolled but PBMC chronically harbored the provirus; in contrast,
in the 8 out 11 macaques protected from an intrarectal challenge,
plasma SIV RNA and PBMC and lymph node cellular SIV DNA
were both undetectable suggesting that SIV infection was blocked
at entry by mucosal immunity or eradicated post-entry by sys-
temic immunity. Surprisingly, we did not observe any SIV-specific
antibodies or interferon γ-producing T-cells in the macaques that
were shown to be protected after intrarectal challenge. Moreover,
CD8+ T-cells isolated from PBMCs of the same macaques strongly
suppressed the replication of virus in acutely infected autologous
CD4+ T-cells ex vivo.
ORAL (INTRAGASTRIC) VACCINATION WITH INACTIVATED SIV AND
LACTOBACILLUS PLANTARUM
Confirmatory studies and new information
Results observed after mucosal vaccination with BCG and iSIV
were very striking, particularly because BCG, an anti-tuberculosis
vaccine given worldwide for more than 90 years to more than a
billion infants and children has never been even suspected to
induce anergy/unresponsiveness or oral tolerance, either to its
own constituents or to those of an immunogen given together.
In view of these unexpected results, we decided to test an oral
vaccine including iSIV and a bacterial adjuvant such as a Lac-
tobacillus strain, a non-pathogenic intestinal commensal bac-
terium that had previously been suggested to potentially favor
immune tolerance (30–32). We started by exploring the activity
of an oral vaccine made of iSIV and LP (33). A group of eight
macaques was immunized via the intragastric route with iSIV for-
mulated with LP while eight control animals received LP only
(four macaques) or iSIV only (four macaques). Results of this
study (23) confirmed and extended several immunological and
virological features already observed in iSIV+BCG-vaccinated
macaques, viz: (1) both SIV-specific antibodies and interferon γ-
secreting T-cells upon SIV Gag p27 stimulation were suppressed
in iSIV+ LP-vaccinated macaques; (2) SIV-positive CD4+ T-cell
activation and SIV replication in infected CD4+ T-cells were also
suppressed (through a non-lytic process) by the CD8+ T-cells of
iSIV+ LP-vaccinated macaques; moreover, ex vivo, suppression
of CD4+ T-cell activation as well as virus replication suppres-
sion did not occur when CD8+ T-cells were omitted from the test
samples; (3) extending our previous work, we also showed that
CD8+ T-cells isolated from the PBMC of vaccinated macaques,
when added to the test samples at a time where SIV-specific CD4+
T-cells activation was already established, no longer inhibited viral
replication; this new information suggested a link of causality
between the suppression of SIV-specific CD4+ T-cell activation
and the suppression of viral replication by CD8+ T-cells. We
further demonstrated that CD8+ T-cell-mediated antiviral activ-
ity required cell-to-cell contact and that vaccine-induced CD8+
T-cells operated through a non-classical MHC-restriction mecha-
nism that was dependent on MHC-IB/E. We also showed that clas-
sical Tregs (CD4+CD25+FoxP3+) had no role in this suppression
process; (4) finally, we demonstrated that, similar to iSIV+BCG-
vaccinated macaques, the eight iSIV+ LP-vaccinated macaques
orally were sterilely protected from high dose intrarectal chal-
lenge (100,000 TCID50) of SIVmac239 (without any detectable
level of plasma SIV RNA or PBMC proviral DNA) while the eight
control animals were infected. This sterile protection was fully
confirmed by the results of a second intrarectal challenge per-
formed in four out of eight vaccinated macaques. We also showed
the same virological picture as that observed in iSIV+BCG-
vaccinated macaques in the four out of eight macaques, which
were rechallenged via the intravenous route; a slight peak of
SIV replication (≤200 DNA copies/million PBMC and 200 SIV
copies/ml of plasma) was observed at day 10 post-challenge, but
by day 30, plasma SIV RNA loads had dropped back to unde-
tectable level (≤10 copies/ml) while PBMC SIV DNA were ≤10
copies/million cells showing the latent presence of SIV proviral
DNA but the absence of virus replication in vivo. Finally, we
showed that the eight iSIVmac239+ LP-vaccinated macaques (the
already four intrarectally rechallenged and the already four intra-
venously rechallenged ones) remained fully protected against an
heterologous intrarectal challenge with 100,000 TCID50 of the
antigenically distinct SIVB670, which suggested that the vaccine
was cross-protective, presumably through preventing the activa-
tion of CD4+ T-cells infected by another SIV strain [see Figure
4 in Ref. (23)]. Results of oral vaccinations with iSIV+BCG and
iSIV+ LP are summarized in Table 1.
Role of CD8+ T-cells in protecting macaques against intrarectal SIV
challenge
To better identify the in vivo role of CD8+ T-cells in the
macaques protection, the four macaques sterilely protected after
three intrarectal challenge were given a fourth intrarectal chal-
lenge with 100,000 TCID50 of SIV239; these four macaques were
at the same time depleted of their CD8+ T-cells from periph-
eral blood and lymphoid organs by a cytotoxic anti-CD8 antibody
[see “Method” in Ref. (23)]. At the nadir of CD8+ T-cell count
(day 15), plasma viral loads of the four animals peaked around
104–106 RNA copies/ml and 103–104 copies SIV DNA/106 PBMC,
respectively, and all animals became infected and SIV-seropositive.
However, by weeks 4–7, when the CD8+ T-cell levels of the four
monkeys had recovered to almost normal, plasma SIV RNA and
PBMC and lymph node SIV DNA dropped to baseline levels. This
in vivo experiment demonstrated the central role of CD8+ T-cells
in immunized animals to prevent initial infection at the mucosal
barrier. When CD8+ T-cells were depleted at the moment of
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Table 1 | Summary of immunovirological results observed in orally
vaccinated monkeys.
Intragastric immunization iSIV iSIV+BCG iSIV+LP
Production of anti-SIV antibodies Yes Suppressed Suppressed
Induction of SIV-specific
IFNγ-releasing T-cells
Yes Suppressed Suppressed
Proliferation of CD4+ T-cells
toward SIV antigens
NT* NT Suppressed
Activation of SIV+CD4+ T-cells Yes Suppressed Suppressed
Ex-vivo suppressive CD8+ Tregs No Yes Yes
Sterile protection after intrarectal
homologous SIV challenge
No Yes Yes
Sterile protection after intrarectal
heterologous SIV challenge
No NT Yes
Absence of SIV replication after
intravenous SIV challenge
No Yes Yes
*NT, not tested.
the intrarectal challenge, the virus replicated freely in lymphoid
organs; but as soon as the vaccine-induced CD8+ T-cell popu-
lation recovered, they again strongly controlled viral replication.
Interestingly, recovered animals now contained SIV DNA in target
cells, but without obvious viral replication (23).
Longevity of the vaccine-induced protection
To study the longevity of the vaccine protection, we immunized
a new group of eight macaques with iSIV/LP in parallel with
eight control macaques (four with iSIV and four with LP). We
observed that seven of the eight animals that received the vac-
cine maintained a high ex vivo antiviral activity ratio (≥200) for
up to 14 months while in one vaccinated macaque the antiviral
activity decreased from month 12 to the baseline ratio (<100)
seen in the eight control animals treated with iSIV or LP alone.
By 14 months post-immunization, all 16 animals (vaccinated and
controls) were challenged intrarectally with 100,000 TCID50 of
SIVmac239. Seven out of the eight iSIV/LP-immunized animals
had a sterile immunity as indicated by the absence of any SIV
RNA and DNA emergence in plasma, PBMC, rectal mucosa, or
pelvic lymph nodes lymphocytes. Interestingly, the one vacci-
nated macaque, which lost its ex vivo antiviral activity became
fully infected in the same manner as the eight control monkeys
[see Figure 5 in Ref. (23); Figures 3A,B]. Thus, the evolution
of the ex vivo antiviral activity of the eight vaccinated mon-
keys allowed us to predict, from day 360 post-immunization (i.e.,
60 days before their challenge) the one out of eight monkeys that
would not be protected. To control further the long-term effi-
cacy of our vaccine, the seven protected macaques were intrarec-
tally rechallenged by 36 months after vaccination; by 48 months
post vaccination, we showed that all of them remained fully
protected from infection (Figures 3A,B); importantly, we con-
trolled that the repetition of viral challenges had no role in
the long-term protection of the vaccinated macaques since their
CD8+ T-cells conserved the same high level of ex vivo antivi-
ral activity before as well as after being rechallenged (data not
shown).
FIGURE 3 | Long-term follow-up of eight macaques intragastrically
immunized with iSIV and LP and eight control monkeys immunized
with iSIV alone (four macaques) or LP alone (four macaques).
(A,B) Plasma viral loads (A) and PBMC proviral loads (B) of eight macaques
submitted to two successive intrarectal challenges performed at 14 and
36 months post-immunization with SIVmac239 (100,000 TCID50).
ORAL (INTRAGASTRIC) VACCINATION WITH INACTIVATED SIV AND
LACTOBACILLUS RHAMNOSUS
Because the Lactobacillus plantarum strain ATCC8014 used to vac-
cinate macaques along with iSIV had never been used in humans,
we tested the common probiotic strain Lactobacillus rhamnosus
(LR) as bacterial adjuvant (34). Four macaques were vaccinated
orally with iSIV and LR; at the same time, four control macaques
received LR only (two animals) and iSIV only (two animals). All
macaques were vaccinated according to the protocol used for
iSIV+ LP vaccination. The ex vivo antiviral activity following
vaccination increased progressively to reach a ratio >200 in all
vaccinated macaques by 2 months post vaccination (Figure 4A).
Moreover, all vaccinated animals were sterilely protected from
an intrarectal challenge (100,000 TCID50 of SIVmac239) per-
formed 12 weeks post vaccination (Figures 4B,C).
In summary, in the macaque model, we have demonstrated
the prevention of SIV infection by inducing immunological tol-
erance against the infectious agent. The administration of iSIV-
mac239 with bacterial adjuvants such as BCG,LP,or LR, stimulated
macaques to develop a thus far unrecognized type of SIV-specific
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FIGURE 4 | Ex vivo antiviral activity induced by CD8+ T-cells of four
macaques intragastrically immunized with iSIV plus LR and viral loads
of the four macaques following an intrarectal challenge. (A) Ex vivo
antiviral activity induced by CD8+ T-cells of four macaques intragastrically
immunized with iSIV and LR and four control monkeys immunized with iSIV
alone or LR alone; (B,C) plasma viral loads (B) and PBMC proviral loads
(C) following an intrarectal challenge performed intrarectally with
SIVmac239 (100,000 TCID50) at day 90 post-immunization.
immune tolerance characterized by the activation of a previously
unrecognized population of non-cytolytic MHCIb/E-restricted
CD8+ T-regulatory cells that have the apparent ability to sup-
press the activation of SIV-positive CD4+ T-cells. This suppression
resulted in the blocking of SIV reverse transcription in CD4+
T-cells thereby preventing the initial burst of virus replication
and thus protecting macaques from infection. Out of 24 intra-
gastrically vaccinated macaques challenged with a high dose of
SIVmac239 or the heterologous strain SIVB670 3 to 14 months
later via the intrarectal route, 23 were sterilely protected for up to
48 months while all control macaques became infected.
DISCUSSION
We have identified three areas of research that will be required to
establish the mechanisms involved in the observed protection.
CHARACTERISTICS OF VACCINE-INDUCED CD8+ T-REGULATORY CELLS
The suppressive non-cytolytic MHC-IB/E-restricted CD8+ T-cells
identified in the present study represent a new class of CD8+
T-regulatory cells (CD8+ Tregs) that has not been described pre-
viously in the context of any antiviral vaccination or in SIV or
HIV infection. Thus far, the only T-regulatory cells described in
HIV infection were classical Tregs (CD25+FoxP3+CD4+ T-cells)
known to be involved in some models of immune tolerance (35).
Their role in HIV infection is not clearly understood; on the one
hand, the expansion of Tregs has been shown to be associated
with the suppression of HIV-specific CD4+ T-cell responses and
disease progression (36, 37) while on the other hand, Tregs have
been associated with protection from productive infection, CD4+
T-cell activation and disease progressions in both humans (38,
39) and non-human primates (40). In the present study, the ex
vivo removal of CD25+FoxP3+CD4+ T-cells by an anti-CD25
antibody did not modify either the suppression of CD4+ T-cell
activation or that of viral replication. Except for the fact that
they are non-cytolytic, the CD8+ Tregs observed here resem-
ble those which targeted and eliminated abnormally activated
antigen-specific CD4+ T-helper cells in the mouse model (41, 42)
where the inhibitory interaction depends on recognition of surface
Qa-1, corresponding to MHC-IB/E in macaques and to HLA-E
in humans (43), expressed by aberrantly activated target cells (44,
45). Similar CD8+ Tregs have also been implicated in the control of
autoimmune type 1 diabetes in humans (46). Interestingly, we also
found CD8+ Tregs with the same characteristics in human elite
controllers, a small percentage of HIV-infected patients (<1%)
who have naturally long-term undetectable viral loads but harbor
the virus in their target cells (Wei Lu and Jean-Marie Andrieu,
manuscript in preparation). So far, we have not been able to iden-
tify the CD antigens specifically associated with these CD8+ Tregs
and their phenotypic and molecular characteristics require further
studies.
ROLE OF CD8+ T-REGULATORY CELLS
Because vaccinated macaques challenged via the intrarectal route
were negative for both SIV RNA in plasma and proviral SIV
DNA in PBMC, our results suggest that virus infection was
arrested before nuclear integration. In quiescent CD4+ T-cells,
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virus penetration is followed within 2 h by the presentation at the
plasma membrane of Gag/Pol and other protein epitopes derived
from incoming virions (47) while Env and Nef protein presen-
tation requires de novo synthesis (48). The subsequent phases of
the infectious process including reverse transcription and proviral
DNA integration, develop very inefficiently in quiescent CD4+
T-cells but very efficiently in activated CD4+ T-cells (49–51).
This is in keeping with the notion that the early activation of a
small founder population of infected CD4+ T-cells at the por-
tal of entry is required for the local expansion and establishment
of systemic infection (52, 53). This early event potentially gives
our vaccine-induced CD8+ T-cells the opportunity to arrest the
infectious process before proviral DNA integration. We observed
that the withdrawal of our vaccine-induced CD8+ T-cells from
PBMC cultures before CD4+ T-cell activation, allowed CD4+ T-
cells to become activated and thereby viral replication to proceed.
Similarly, in vivo depletion of the CD8+ T-cells performed at the
time of intrarectal challenge allowed CD4+ T-cells to be activated
and the virus to replicate. Such replication, however, was brought
under control as the novel CD8+ T-cells recovered in lymphoid
organs and the blood stream. We showed in ex vivo cultures that
the inhibition of viral replication was directly attributable to this
new class of CD8+ Tregs. This is also highly likely to be the case
in vivo although direct evidence for this is lacking since we depleted
the whole CD8+ T-cell population rather than specifically the Treg
subset. In monkeys intravenously challenged, the transient peak of
viral replication followed by the residual presence of cellular SIV
DNA suggested that infectious SIV particles that entered the body
by this route encountered activated CD4+ T-cells, probably in
secondary lymphoid organs, which allowed the virus to complete
the first cycles of replication. However, it cannot be excluded that
non-activated (quiescent) CD4+ T-cells, which were penetrated by
newly released virions, were prevented from becoming activated
by the vaccine-generated CD8+ Treg. An in-depth understand-
ing of the results presented here will require extensive exploratory
studies of cellular and molecular immunovirology.
INDUCTION OF SIV-SPECIFIC CD8+ T-REGULATORY CELLS
This remains the most mysterious unanswered question. When
iSIV, a particulate immunogen was administered alone via the
intragastric route, it stimulated the intestinal immune system
to induce the activation and proliferation of SIV-CD4+ T-cell
as well as the generation of SIV-specific antibodies and inter-
feron γ-producing cells according to the classical vaccine para-
digm. However, this iSIV-only vaccination did not induce any
in vitro or in vivo viral suppression nor any protection in chal-
lenged macaques. On the other hand, a soluble protein such as
SIV P55, when intragastrically administered in its own, did not
induce any immunological response nor any challenge protec-
tion (data not shown). In surprising contrast, when iSIV was
administered along with BCG, or LP or LR, the reaction of the
macaque intestinal immune was totally different. SIV-CD4+ T-
cells proliferation and activation were abolished (through the
contact between the TCRαβ of the vaccine-induced CD8+ T-
regulatory cells and the MHCIb/E of SIV positive CD4+ T-cells).
A first consequence of this vaccine-induced SIV-positive CD4+
T-cell unresponsiveness/anergy is most likely the suppression of
any help to the induction of SIV-specific antibody- and interferon
γ-producing cells; the observation of such an antigen-specific
immune tolerance opens a vast array of research on the sup-
pressive arm of the immune system and its potential manipu-
lation in human and veterinary medicine. The other consequence
of this vaccine-induced SIV-positive CD4+ T-cell unresponsive-
ness/anergy is of unique importance for vaccinologists since it is
responsible for the suppression of in vitro and in vivo SIV reverse
transcription and for the sterile protection of macaques against
SIV challenge, bringing the experimental confirmation of our ini-
tial suspicion that suppression of CD4+ T-cell activation is able to
suppress viral replication (9).
The mechanism of this extraordinary immunological switch is
so far unknown. BCG itself has never been suspected to possess
tolerogenic properties. Only in Brazil, have infants been given BCG
via the oral route (over a period of 50 years from the 20s to the
70s) and Brazilian scientists found that oral BCG protected against
childhood tuberculosis, meningitis, and miliary disease with the
same efficacy as intradermic BCG (54). However, orally vacci-
nated infants remained generally unresponsive/anergic to the post
vaccination tuberculin test, which became generally positive after
classical intradermic vaccination (55). In the same line, oral BCG
vaccination inhibited delayed-type hypersensitivity to purified
protein derivative (while at the same time it induced interferon γ-
secreting T-cells upon Mycobacterium antigens stimulation) (56).
Moreover, it has also been observed that when the central ner-
vous system of mice was infected with BCG, the mice were able to
overcome experimental autoimmune encephalomyelitis, a classi-
cal mice model of autoimmune disease (57). The possibility that
BCG may possess certain unexplored tolerogenic properties seems
worthy of further research inasmuch as CD8+ Tregs have been very
recently shown to dominate suppressive phenotype and function
after BCG activation of human cells (58).
On the other hand, there is some experimental evidence sug-
gesting that LP and LR may have some tolerogenic properties (30–
32), which may be involved in their probiotic ability to fight human
inflammatory bowel disease (59). However, the mechanism of
induction of such a tolerance seems to be via the generation of
classical CD25+FoxP3+CD4+ Tregs (60, 61) and not through the
intervention of CD8+ Tregs.
It must be mentioned that recombinant BCG expressing viral
antigens including HIV and SIV proteins has been tested via the
mucosal route in non-human primates. These recombinant BCGs
induced IgA against BCG-expressed viral proteins but were never
found to induce any humoral or cellular sign of virus-induced
immune tolerance (62). Similarly, lactobacilli and lactococci engi-
neered to express antigenic proteins also including SIV antigens
have been mucosally administered to different animal models
including non-human primates; whatever the antigen expressed,
the immunological result of the mucosal administration was
always the production of specific of antigenic protein-directed
antibodies and particularly of IgA by the intestinal immune
system (63).
Our results demonstrate that an oral vaccine comprising iSIV, a
particulate immunogen adjuvanted by BCG, LP, or LR admin-
istered intragastrically to a large number of macaques stimu-
lated their intestinal immune system and generated a new class
of CD8+ Tregs that suppressed the activation of mucosal and
systemic SIV-positive CD4+ T-cells. This suppression of CD4+
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T-cell activation inhibited viral replication and thereby prevented
SIV infection in the macaque model. The protective effect of this
innovative immunization regimen against SIV challenge, together
with the identification of a correlate of protection ex vivo, is quite
striking. Given that SIV and HIV require activated CD4+ T-cells
in which to replicate, this tolerogenic vaccine approach may offer
an exciting new avenue in preventive HIV vaccine research. We are
preparing a randomized phase 1 trial where a small population
of non-at-risk volunteers will receive the vaccine or a placebo;
the vaccination success will be defined by the increase of the ex
vivo antiviral activity of CD8+ T-cells (ratio >200) in the vac-
cinated group while it will remain low and stable (ratio <100)
in the placebo group. On the other hand, the de novo induction
of this class of CD8+ Tregs could potentially be used therapeuti-
cally to maintain HIV replication suppression in infected patients
in whom antiviral treatments have been interrupted. We are now
preparing a phase 1 trial where infected volunteers with unde-
tectable viral loads under antiviral therapy will be orally vaccinated
with heat-inactivated HIV and LR; the antiviral treatment of
infected volunteers will be suspended at week 24. The success of
this trial will be ascertained by the increase of ex vivo antiviral
activity of CD8+ T-cells (ratio >200) by 8 weeks post vaccina-
tion and by permanent undetectable plasma viral loads from week
24 (antiviral treatment withdrawal). The new tolerogenic vaccine
paradigm described in the present study, beside its potential use in
the HIV vaccine field, could potentially be exploited in the man-
agement of a wide range of immune disorders and could uncover
so far unrecognized immunological mechanisms.
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